

Diversity and distribution of sulphate-reducing bacteria in human faeces from healthy subjects and patients with inflammatory bowel disease

Wenjing Jia¹, Rebekah N. Whitehead¹, Lesley Griffiths¹, Claire Dawson², Hao Bai³, Rosemary H. Waring¹, David B. Ramsden¹, John O. Hunter², Michael Cauchi⁴, Conrad Bessant⁴, Dawn P. Fowler⁴, Christopher Walton⁴, Claire Turner⁵ & Jeffrey A. Cole¹

¹School of Biosciences, University of Birmingham, Birmingham B15 2TT, UK; ²Gastroenterology Research Unit, Box 262, Addenbrookes Hospital, Cambridge CB2 0QQ, UK; ³School of Electronic, Electrical and Computer Engineering, University of Birmingham, Birmingham B15 2TT, UK; ⁴Cranfield Health, Vincent Building, Cranfield University, Bedfordshire MK43 0AL; ⁵The Department of Life, Health and Chemical Sciences, Open University, Milton Keynes, MK7 6BJ, UK;

Correspondence: Jeffrey Cole, School of Biosciences, University of Birmingham, Birmingham B15 2TT, UK. Tel.: +44 121 414 5440; fax: +44 121 4145925; e-mail: j.a.cole@bham.ac.uk

Running title: Sulphate-reducing bacteria in human faeces

Key words: faecal sulphate-reducing bacteria, diversity, 454 sequencing, Irritable Bowel Syndrome, Crohn's Disease, Ulcerative Colitis

17 **Abstract**

18 The relative abundance of different groups of sulphate reducing bacteria (SRB) in faecal DNA
19 collected before and after therapy from patients suffering with Crohn’s disease (CD), irritable bowel
20 syndrome (IBS) or ulcerative colitis (UC) has been compared with that from healthy controls. Growth
21 tests revealed that SRB were not more abundant in samples from CD patients before treatment than in
22 the healthy control group. For most of the 128 samples available, these preliminary results were
23 confirmed using degenerate PCR primers that amplify the *dsrAB* gene. However, some samples from
24 CD patients before treatment contained a growth inhibitor that was absent from IBS or UC samples.

25 In-depth sequencing of PCR-generated *dsrB* fragments revealed that the diversity detected was
26 surprisingly low, with only 8 strains of SRB and the sulphite reducing bacterium, *Bilophila*
27 *wadsworthia*, detected above the 0.1% threshold. The proportion of the two major species detected, *B.*
28 *wadsworthia* and *Desulfovibrio piger*, was as high as 93.5% of the total SRB population in the healthy
29 control group, and lower in all patient groups. Four previously undescribed species were found: it is
30 impossible to predict whether they are sulphate or sulphite reducing bacteria.

31

32 **Introduction**

33 A common feature of inflammatory bowel diseases (IBD) such as Crohn’s disease (CD) and ulcerative
34 colitis (UC) is the excessive immune response to bacteria that inhabit the intestinal lumen. Despite
35 recent progress in defining factors that exacerbate or ameliorate these diseases, their precise causes
36 remain poorly defined. Both can be treated with different degrees of success by immunosuppressive
37 drugs such as corticosteroids, azathioprine or infliximab. Although enteral feeding to control dietary
38 intake is effective in the treatment of Crohn’s disease, this is not so in ulcerative colitis (King *et al.*,
39 1997). Successful treatment of Crohn’s disease is accompanied by substantial changes in the
40 composition of gut microbiota and related immunoglobulins (van den Waaij *et al.*, 2004) but no single
41 group of bacteria has been implicated as the unequivocal source of these diseases. Irritable bowel
42 syndrome (IBS) is a condition arising from a variety of causes whose symptoms are often similar to
43 those of IBD. No intestinal inflammation is present, but as many as 50% of cases have food
44 intolerances so that symptoms may be controlled successfully by diet (Wiesner *et al.*, 2009). These
45 intolerances have been shown to be related to abnormal fermentation by the colonic microflora (King *et*
46 *al.*, 1998, Dear *et al.*, 2005).

47 Two of the major groups of bacteria that dominate the human gut are those that ferment
48 complex carbohydrates, lipids or protein to lactate; and those that convert lactate to propionate or
49 butyrate. The production of butyrate is significant because it is the preferred energy source for
50 colonocytes (Macpherson *et al.*, 1996; Aminov *et al.*, 2006; Louis & Flint, 2009; Mai & Draganov,
51 2009) and is both anti-inflammatory and anti-carcinogenic (Hamer *et al.*, 2008; Tazoe *et al.*, 2008). It
52 is converted by gastrointestinal bacteria to other compounds that are also anti-inflammatory (Sokol *et*
53 *al.*, 2008). Butyrate is generated from lactate by fermentative bacteria dominated by the *Firmicute*
54 phylum, and a marked deficiency of one species, *Faecalibacterium prausnitzii*, has been suggested as

being correlated with Crohn's disease. However, this report is unconfirmed because successful treatment with enteral diet resulted in a decrease, not an increase, in *F. prausnitzii* in this patient group (Jia *et al.*, 2010). There was no significant deficiency in *F. prausnitzii* either before or after treatment of ulcerative colitis or irritable bowel syndrome patients.

It has been proposed that the production of an unidentified toxin by intestinal bacteria might play a significant role in provoking intestinal inflammation. Anecdotally, in an acute phase, Crohn's disease patients suffer from bad breath typical of hydrogen sulphide production, and the presence of high levels of sulphide in their faecal samples has been documented (Pitcher & Cummings, 1996). Some sulphate reducing bacteria (SRB) generate sulphide from sulphate using lactate as their preferred electron donor, and hence they compete with *Firmicutes* for their primary source of carbon and energy (Roediger *et al.*, 1997; Chapman *et al.*, 1994; Attene-Ramos *et al.*, 2007). It has therefore been proposed that sulphate reducing bacteria exacerbate gastrointestinal disease not only by generating a toxic product, hydrogen sulphide, but also by depleting the production of beneficial butyrate (Marquet *et al.*, 2009; but see also Shatalin *et al.*, 2011). If so, sulphate reducing bacteria might be less abundant in patients after successful treatment. Mills *et al.* (2008) reported that after continuous flow culture models of the human colonic microbiota were inoculated with faeces from UC and non-UC volunteers, changes in bacterial populations were observed, with elevated numbers of sulphate reducing bacteria in the microbiota from UC patients. Furthermore, it is possible that one or more species of sulphate reducing bacteria might be associated with gastrointestinal disease. A previous study has revealed that the prevalence of *Desulfovibrio piger* was significantly higher in inflammatory bowel disease patients as compared to healthy individuals (Loubinoux *et al.* 2002). However, results from the literature do not show a clear association between sulphate reducing bacteria and IBD (Zinkevich and Beech, 2000;

77 Pitcher *et al.*, 2000; Duffy *et al.*, 2002; Ohge *et al.*, 2005; Manichanh *et al.*, 2006; Collado *et al.*, 2007).
78 This might reflect highly diverse microbiota within individual groups and differences in methodology.

79 To investigate the possible association between gut disease and SRB, we compared the relative
80 abundance of sulphate reducing bacteria in faecal DNA collected before and after therapy from patients
81 suffering with Crohn's disease, irritable bowel syndrome or ulcerative colitis; healthy subjects were
82 also recruited as controls. In addition to conventional methods used in previous studies, such as
83 recovering growth of SRB, PCR and denaturing gradient gel electrophoresis (DGGE), the diversity of
84 SRB in human faeces was also studied by next-generation sequencing (454 sequencing, Roche), which
85 allows the identification of SRB species at a DNA level.

86 **Materials and methods**

87 **Patient recruitment and treatment**

88 Faecal samples were collected from 21 IBS patients, 20 CD patients and 14 UC patients, as described
89 previously (Jia *et al.*, 2010). As controls, 18 healthy subjects were also recruited. Briefly, all volunteers
90 were recruited at Addenbrookes Hospital, Cambridge, which functions as a tertiary referral centre for
91 IBD. Ethical permission to collect these samples was obtained from Leeds West Ethics Research
92 Committee (Ref. 07/Q1205/39) and informed, written consent was obtained from each subject. The
93 diagnosis of CD and UC was based on standard endoscopic, radiological and histological findings; all
94 subjects with IBS fulfilled the Rome II criteria. The severity of CD symptoms was reflected by the
95 Harvey and Bradshaw (1980) Index and an objective measure of inflammation was provided by the
96 serum concentration of C-Reactive Protein (CRP), which was determined by the Clinical Biochemistry
97 Department, Addenbrookes Hospital. The patients gave a faecal sample at the start of treatment and in

most cases again after treatment. Within 48 hours of collection, samples (at 4°C) were sent by courier to the University of Birmingham for DNA extraction and preparation of faecal suspension.

CD patients were treated as described previously (Jia *et al.*, 2010). Apart from water *ad libitum*, their nutritional intake was limited to the elemental diet E 028 Extra (Nutricia, Liverpool UK) in quantities calculated individually by a registered dietician according to the Schofield (1985) equation until symptoms resolved, which took two to three weeks. Further faecal samples were collected when they reached remission. Eleven of the UC patients had received either immuno-modulation or 5-aminosalicylic acid therapy prior to this study, and this was continued or introduced for all of the UC group, albeit with changes in the drugs prescribed, and increases in the doses used. IBS patients received conventional treatment with either low-fibre diet or non-fermentable bulking agents such as sterculia. (Weisner *et al.*, 2009). Again, further faecal samples were obtained when the patients reached remission.

DNA extraction and templates preparation for 454 sequencing

DNA was extracted from each faecal sample and stored as reported previously (Jia *et al.* 2010). To amplify a DNA fragment that is definitive for SRB in environmental DNA, a semi-nested PCR strategy (the first round to amplify *dsrAB* followed by a second round to amplify *dsrB*) has proven to be much more effective for detecting the widest range of species than using only one round of PCR and was therefore employed by this study (Miletto *et al.* 2007). First, 5 forward and 6 reverse degenerate primers were used to amplify an approximately 1.9 kb *dsrAB* fragment from as many SRB as possible (Supplementary Table 1). In a total volume of 20 µl, 10 ng of DNA was used as a template with HotStarTaq Plus Master Mix Kit (Qiagen) plus 4 µl of Q-solution (Qiagen) according to the manufacturer's instructions. The reaction conditions were: initial denaturation (5 min at 95°C); then 12

cycles of denaturation (40 s at 94°C), annealing at temperatures ranging from 60 to 48°C (decreasing 1°C per cycle, 40 s) and elongation (2 min at 72°C); followed by 23 cycles of denaturation (40 s at 94°C), annealing (40 s at 48°C) and elongation (2 min at 72°C); and a final extension (10 min at 72°C). The PCR product was then used as a template for a second round of PCR to amplify an approximately 430 bp *dsrB* fragment including a barcode (also called multiple identifiers, MID) that could represent a patient group and be recognised in the following analysis. The design of primers used for the second round of PCR was based on previous publications (Geets *et al.*, 2006; Miletto *et al.* 2007) and was made more degenerate to rescue as many SRB species as possible (Supplementary Table 1). The reaction conditions were: initial denaturation (5 min at 95°C); then 30 cycles of denaturation (40 s at 94°C), annealing (40 s at 55°C) and elongation (1 min at 72°C); and a final extension (10 min at 72°C).

Qualitative estimation of SRB abundance in faeces

By using a homogeniser, a 0.4 g faecal specimen from each subject was suspended in 3.6 ml of peptone water. The suspension was centrifuged at 100 x *g* for 40 s to remove any remaining solid matter and the supernatant was collected and centrifuged at 12,000 x *g* for 5 min. The pellet obtained was then washed twice in 1 ml of TE buffer (10 mM Tris-Cl pH 7.5 containing 1 mM EDTA). The final pellet was resuspended in 4 ml of TE buffer supplemented with 100 µl of 40% glycerol, and the suspension was aliquoted and stored at – 80°C. To recover the growth of SRB that are able to use lactate as their electron donor and sole source of carbon, 0.5 ml of faecal suspension was inoculated into a 9.5-ml sulphate-rich growth medium, Postgate B (Postgate, 1984). The cultures were grown anaerobically in sealed 10 ml serum bottles. After incubation at 30°C for 21 days, they were photographed and the digital pictures were analysed to measure the degree of blackening of the culture. The abundance of SRB was gauged according to the amount of black precipitate, ferrous sulphide, formed by SRB. The

142 pure black colour was defined as 99, whereas pure white was defined as 0. The black intensity of each
143 culture was determined accordingly, ranging from 4 to 73.

144 Because the capacity of Postgate B medium to recover all SRB is not known, the abundance of
145 SRB in faeces was also estimated by PCR. The production of a *dsrB* fragment following two rounds of
146 PCR was gauged. In the first round, 10 ng of faecal DNA was used as a template; and in the second
147 round, 0.5 µl of the first round PCR product was included in all photographs and used for
148 normalization. The final PCR product (10 µl) was loaded on a 0.8 % agarose gel to check for a specific
149 band with a length of approximately 430 bp. The samples were divided into five groups based on the
150 production of *dsrB*: score 1, no specific band could be detected; score 2, a weak band was detected
151 when the undiluted first round PCR product was used as a template; score 3, a strong band was
152 detected when the undiluted first round PCR product was used as a template; score 4, a strong band
153 was detected when a 10-fold dilution of first round PCR product was used as a template; and score 5, a
154 strong band was detected when a 1000-fold dilution of first round PCR product was used as a template.

155 **Denaturing Gradient Gel Electrophoresis**

156 The same nested PCR strategy was used to prepare template DNA for DGGE. The product from the
157 first round of PCR, *dsrAB*, was used as a template to amplify *dsrB* but with a 40-bp GC clamp (Miletto
158 *et al.* 2007). The design of primers used for second round of PCR was based on previous publications
159 (Geets *et al.*, 2006; Miletto *et al.* 2007) and was made more degenerate to rescue as many SRB species
160 as possible (Supplementary Table 1). An alignment of *dsrB* sequences has revealed that the improved
161 primers should be effective for over 95 % of all known SRB (allowing 2 mismatches). The reaction
162 conditions were: initial denaturation (5 min at 95°C); then 30 cycles of denaturation (40 s at 94°C),

annealing (40 s at 55°C) and elongation (1 min at 72°C); and a final extension (10 min at 72°C). The *dsrB*-GC PCR product was purified by using QIAquick Gel Extraction Kit (Qiagen, Germany).

In order to reveal the diversity of SRB, the *dsrB*-GC fragments (with the GC clamp) derived from different species in each patient were separated by DGGE using the DCode Universal Mutation Detection System (Bio-Rad, USA). A gradient of 40 to 70% denaturant was constructed in a 1 mm thick 8% (w/v) polyacrylamide gel by mixing a high density solution (70%) with a low density solution (40%) using the Gradient Delivery System. The 100% (w/v) denaturant solution contains 7 M urea and 40% (v/v) formamide. To visually check the formation of the gradient, 300 µl of DCode dye solution was added into 15 ml of high density solution. The purified PCR product was mixed with 6 x bromophenol blue loading buffer and loaded into the parallel gradient gel. Prior to loading, the gel had been pre-heated to 60°C in 7 litres of 0.5 x TAE buffer. The gel was initially run at 150 V for 5 min without circulating the TAE buffer in the tank to facilitate the access of PCR products into the gel, and then at 75 V for 21 h at 60°C with the buffer circulating continuously. Following electrophoresis, the gel was stained for 30 min in 250 ml of 0.5 x TAE buffer containing 1 µg.ml⁻¹ ethidium bromide. The gel was photographed in a UV transilluminator and each *dsrB*-GC band representing a different SRB resource was removed and soaked in 130 µl of nuclease-free water. After eluting DNA into water overnight, a solution containing 50 ng of DNA was evaporated down to 7 µl and sequenced by using primer DSR4R. The sequencing data were analysed using NCBI blast.

Identification of SRB in human faeces by 454 sequencing

Four groups of subjects were recruited in this study to produce seven groups of samples: patients with IBS before and after treatment; patients with CD before and after treatment; patients with UC before and after treatment; and one healthy control group. Unlike the control group, in which a *dsrB* fragment

185 was amplified successfully from every sample, some patients did not carry any SRB that could be
186 amplified and therefore 454 sequencing could not be undertaken. As a result, only 9 subjects in each
187 group were selected and equimolar amounts of template from each patient were pooled. When a before-
188 treatment group was compared with the corresponding after-treatment group, the sequencing data were
189 not for completely paired patients. For the before- and after-treatment UC groups, 7 out of 9 patients
190 were paired; for the 2 CD groups, 5 out of 9 patients were paired; and for the 2 IBS groups, 3 out of 9
191 patients were paired. The 7 patient pools were sequenced by the Functional Genomics and Proteomics
192 Laboratory at the University of Birmingham, and 200,133 sequences were extracted.

193 The sequencing data were analysed by using software Geneious® (Biomatters Ltd, New
194 Zealand). The sequences with low quality (shorter than 150 bp or longer than 440 bp, 15.3% of total)
195 were removed before further analysis. For each pool, 24,220 high-quality sequences were produced on
196 average (169,539 sequences in total). In order to handle the data efficiently, the data produced for one
197 pool were further divided into batches, each comprising approximately 2,500 sequences. They were
198 then aligned by using software MUSCLE, and a neighbour joining phylogenetic tree was constructed
199 based on the alignment result. The distance between clusters in a tree reflects the diversity of SRB
200 found within a patient pool. Sequences within one cluster (diverging distance less than 0.03) were
201 extracted and a consensus sequence was produced. Consistent with the report of Kjeldsen *et al.* (2007),
202 clusters whose consensus amino acid sequences were over 97% identical were considered as one
203 phylotype. Duplicate samples of high quality sequences were analysed from 7 of the pools to check that
204 sufficient data had been analysed to generate a reproducible result. In total, 55,708 out of 169,539
205 sequences were analysed as 21 datasets, which generated 21 phylogenetic trees (Supplementary figures
206 1 – 21). A further comparison between the trees revealed that there were 16 phylotypes, i.e. 16
207 sulphate- or sulphite-reducing bacterial species. In addition, 10 to 20% of the sequences within each

208 bacterial group were analysed using NCBI blast, and the identification reports validated the grouping
209 method based on alignment. The DNA consensus sequences were also translated into amino acid
210 sequences, which again confirmed the grouping method. Furthermore, each patient group could be
211 considered as two sub-groups, because four samples from one group were pooled and labelled with a
212 unique barcode whereas the other five were labelled with a different barcode. Comparison of the two
213 subgroups revealed whether the diversity of SRB was consistent. By combining data for the two
214 subgroups, it was possible to determine whether one patient group as a whole was different from other
215 groups.

216 In addition to the study based on pooled samples, 6 before-treated CD patients were analysed
217 individually by 454 sequencing. To investigate whether the composition of SRB populations had
218 changed in response to the ED therapy, the treated samples from 4 out of the 6 patients were also
219 sequenced. Samples from the three control subjects were also sequenced to test whether the
220 composition of SRB was similar between healthy controls.

221 **Statistical analysis of the data**

222 Results were assessed by non-parametric methods: Mann-Whitney U (MWU) test to compare the
223 healthy control group with patient groups; and Spearman r for correlation analysis. These analyses
224 were carried out using the InStat statistical package (GraphPad).

225 **Results**

226 **The abundance of SRB in faecal suspensions from different patient groups**

227 In this study, 128 faecal samples were donated by 7 groups of patients: CD, UC and IBS patients both
228 before and after treatment, and one healthy control group. For the 128 samples, the abundance of SRB

was estimated by assessing the amounts of ferrous sulphide produced by SRB after aliquots of faecal suspensions had been grown anaerobically in Postgate medium B. Depending on the abundance of SRB in each inoculum, a black precipitate of iron sulphide had accumulated after 1 to 14 days. After 21 days at 30°C, the intensity of the black precipitate in each culture was measured by densitometry (Table 1). The resulting data for each patient group were analysed using the Mann-Whitney test to detect differences between groups. This analysis revealed that there was significantly less growth of SRB in samples from CD patients before treatment than in the healthy control group (Mann Whitney test, $p=0.017$). There had been little change in SRB abundance following enteral diet treatment, but almost certainly due to the small number of samples available for analysis, the P value for the difference compared with the healthy control group had increased to 0.065. Samples from UC patients before treatment also appeared to give less SRB growth compared with the healthy control group, but due to the small number of samples available, this apparent difference was not statistically significant. In contrast, there were no significant differences between the healthy controls and the IBS patients either before or after treatment.

The abundance of SRB DNA in faecal DNA determined by PCR analysis

Dissimilatory sulphite reductase encoded by *dsrAB* is an essential and highly conserved enzyme in sulphate reducing bacteria. The occurrence of similar sequences is limited to organisms that reduce other sulphur compounds such as organosulphates or sulphite and to sulphur oxidizing that are unlikely to be abundant in human faeces. Degenerate primer sets have been developed that amplify a 1.9 kb fragment of the *dsr* operon from virtually all known SRB (Zverlov *et al.*, 2005). These primers were used to amplify PCR products using faecal DNA as template. The abundance of SRB in each sample was estimated on the basis of the quantity of DNA template required to amplify a PCR product that was visible by gel electrophoresis (Table 1). This independent qualitative method for estimating the

252 abundance of SRB also revealed significantly less SRB DNA in faecal samples from CD patients and
253 in the healthy control group. Statistical analysis again revealed that this difference compared with the
254 healthy control group was statistically significant before treatment (Mann Whitney test $p=0.0136$): the
255 p value for the comparison of the post-treatment samples with the control group was 0.066. As for the
256 growth-dependent assays, there were no significant differences in the abundance of *dsrB* DNA in
257 samples from UC and IBS patients and the healthy control group either before or after treatment.

258 **Comparison of data for individual samples obtained by growth experiments and PCR analysis**

259 There was a significant correlation between the estimated relative abundance of SRB obtained for each
260 individual sample by using the two independent methods (Supplementary Fig. S22: Spearman $r=$
261 0.3994, $p<0.01$, number of XY pairs = 125; culture data were not available for 3 patients). It was
262 therefore concluded that, to a first approximation, both methods provide valid qualitative estimates of
263 the relative abundance of SRB in faecal samples, and therefore that the PCR approach could be
264 extended to compare the diversity of SRB within and between samples.

265 **Inhibition of SRB growth by faecal suspensions from some CD patients**

266 Despite the significant correlation between results of growth tests and PCR analysis of faecal DNA,
267 clear discrepancies were apparent in the results from the two methods for some of the CD samples. For
268 each of the 18 healthy controls, both growth tests and PCR amplification data indicated a high
269 abundance of SRB, and the ratios of the two scores ranged between 11 and 18 (on average 15). In
270 contrast, in 8 out of the 22 samples from CD patients before treatment, PCR analysis revealed a high
271 level of SRB DNA, but relatively low SRB growth occurred when suspensions were used to inoculate
272 Postgate medium B. The ratios of the two scores for these 8 samples were all below 11, including a
273 ratio of 2 for sample 82 and less than 1 for sample 148. This lack of growth despite the presence of

274 SRB DNA might indicate either that the SRB in these samples were no longer viable, or that the major
275 SRB species present grew poorly in Postgate medium B. A further possibility was that the faeces
276 contained an inhibitor of SRB growth. To investigate whether samples 82 and 148 from CD patients
277 before treatment contain an inhibitor of SRB growth, 0.5 ml of faecal suspension from these two
278 samples was incubated in Postgate medium B with samples 116 or 126 in which SRB growth was rapid
279 and abundant. Both samples strongly inhibited the growth of the positive controls (Fig. 1a and 1b).
280 Dilution of these samples resulted in progressively less growth inhibition of the positive controls,
281 confirming that inhibition was concentration-dependent. Growth inhibition was also lost on subsequent
282 subculturing, presumably also due to dilution of the growth inhibitor in the original faecal sample (Fig.
283 1c). Sample #82 was from patient CG before treatment: the post-treatment sample #88 from this
284 patient was also incubated with SRB-positive controls: it did not inhibit SRB growth (Fig. 1b). Further
285 investigation established that 6 out of the 8 samples that gave poor SRB growth contained inhibitory
286 factors for the growth of SRB, and in all six cases, growth inhibition was lost or had decreased
287 substantially in samples from the same patient post-treatment. Samples from IBS and UC patients in
288 which SRB DNA was abundant but growth in Postgate medium B was poor were also tested for the
289 presence of growth-inhibitory factors. None of these samples inhibited growth of the positive controls.

290 **DGGE investigation and sample selection for 454 sequencing**

291 In initial experiments, the 1.9 kb *dsrAB* fragments were used as templates to generate 390 bp PCR
292 products with clamps suitable for analysis by DGGE. To provide standards to calibrate DGGE gels,
293 PCR products were also generated from DNA isolated from pure cultures of well-characterised
294 sulphate reducing bacteria, and also from *B. wadsworthia*. Multiple bands following electrophoresis
295 revealed the presence of PCR products of different GC content, suggesting the presence of a range of
296 different SRB in these samples (Supplementary figure S23). However, multiple bands were also

297 obtained from PCR products generated using the same set of degenerate primers and chromosomal
298 DNA purified from pure cultures of known SRB. Bands extracted from some of these gels were
299 sequenced, and their origins were confirmed. By using NCBI blast, three species, *B. wadsworthia*, *D.*
300 *vulgaris* Hildenborough and *Desulfovibrio* sp. NY682 were found in the samples tested. However,
301 extensive experiments with this technique gave data too variable for reliable use in detecting minority
302 populations or in determining the relative abundance of different SRB groups. The method was also too
303 insensitive to detect minority populations that might be relevant to disease. The DGGE analysis was
304 therefore abandoned in favour of in-depth DNA sequencing of PCR products.

305 **Diversity of sulphate reducing bacteria in human faecal DNA**

306 The 1.9 kb *dsrAB* fragment was readily generated using faecal DNA from all of the 18 samples from
307 the control group, and all of these faecal samples gave abundant growth of SRB in Postgate medium B.
308 Nine of these samples were used as templates to generate two pools (one pool from five samples and
309 the other from four samples) of 430 bp bar-coded PCR products suitable for in-depth DNA sequencing.
310 A further 12 pools of 430 bp bar-coded PCR products were also generated from faecal DNA from CD,
311 UC and IBS patients before and after treatment (Table 2). As a result, the 454 sequencing data would
312 reflect the most abundant SRB species present in the samples. However, the profile for CD and UC
313 patients would not be quite complete because it was impossible to include samples from which *dsrB*
314 fragments could not be amplified.

315 Equal quantities of DNA from each of the 14 resulting pools were mixed and sequenced. The
316 14 pools yielded 169,539 DNA sequences of good quality, of which over 99% could unequivocally be
317 assigned to a *dsrB* fragment from an SRB in an identified pool of PCR products. The numbers of

318 sequences obtained from individual pools ranged from 1,591 in one of the pools of samples from IBS
319 patients after treatment to 24,100 sequences from a pool of UC patients after treatment.

320 As a first step in data analysis, the diversity and relative numbers of SRB amongst over 2,500
321 randomly selected sequences were then analysed and compared with a further 2,500 sequences from
322 the same sample. The results of these duplicate analyses were essentially identical (Supplementary Fig.
323 S24), suggesting that it was sufficient to analyse 2,500 sequences from each pool to detect species
324 present at more than 0.1% of the total SRB population.

325 The diversity of SRB in each pool was then determined, as described in detail in the Methods
326 section. As shown in Table 2, each of the 7 patient groups could be considered as two sub-groups. The
327 two sub-groups were compared to determine whether the diversity of SRB was consistent within one
328 patient group; and, when the results of the two sub-groups were combined, whether one patient group
329 as a whole was different from others (Fig. 2 - comparison between 7 patient groups; Table 3-
330 comparison between 2 subgroups within one patient group).

331 The diversity and relative distribution represented in the 14 pooled samples were then
332 determined by analysis of 55,708 sequences out of the 169,539 good-quality sequences available
333 following 454 sequencing. There were two key observations from this initial series of experiments.

334 First, the diversity detected was surprisingly low, with only 8 groups of *dsrB* sequences other
335 than the sulphite reducing bacterium, *B. wadsworthia*, detected above the 0.1% threshold (Fig. 3). Four
336 of the SRB are either identical or closely related to known species: *D. piger*; *D. vulgaris*
337 Hildenborough; *D. sp. NY682*; and *D. desulfuricans* F28-1. Note that the remaining four species might
338 not be SRB, but bacteria able to reduce sulphite or organic oxidized sulphur compounds.

339 Secondly, four previously undescribed species designated strains A, B, C and D were found:
340 strains A and B were more widely distributed than strains C and D. Because these results were from
341 pools of DNA samples from 4 or 5 individuals, these strains might have been carried by only one or
342 two people. Database searches revealed that on the basis of the *dsrB* sequences, the closest relative to
343 species A is *D. desulfuricans* F28-1 (93% sequence identity); *dsrB* from species B is 84% identical to
344 that from *D. oxamicus*; *dsrB* from C is 80% identical to *Desulfotomaculum* sp. Lac2; and D is 88%
345 identical to *D. simplex*. It is impossible to predict whether the 4 new bacterial groups have sulphate or
346 sulphite reducing capacity as they are so different from any known bacteria (Fig. 3; Table S2).

347 **Relative abundance of SRB in faeces**

348 The data described above enabled the relative abundance of the various strains to be calculated. *D.*
349 *piger* was the most abundant SRB present in 9 of the 14 pools. However, its abundance varied widely
350 from pool to pool and no consistent trends were apparent. For example, *D. piger* was not detected in
351 one of the samples, pool 11, from IBS patients before treatment but constituted 44.7% of the *dsrB*
352 sequences in the other pool of patients (pool 4; Table 3). There was similar variation in the abundance
353 of *D. piger* in pools from IBS patients post-treatment, with none detected in pool 12, but 36% in pool 5.
354 *B. wadsworthia* was more abundant than all of the SRB in 9 of the 14 pooled samples, but again its
355 relative abundance varied widely between pools (Table 3).

356 **Distribution of SRB in individuals**

357 The most significant differences in SRB populations revealed by PCR analysis were between CD
358 patients before treatment and the healthy controls. In order to identify any differences in SRB
359 populations before and after treatment, 13 individual samples were investigated, including 3 healthy
360 controls, 4 pairs of CD patients both before and after treatment, and 2 other CD patients before

361 treatment (Table 4). In the 3 healthy individuals, the proportion of the 2 major species contributed over
362 90% of all *dsrB* sequences, similar to the pooled data. However, the ratios of *B. wadsworthia* to *D.*
363 *piger* varied over a wide range. Among the 6 CD patients before treatment, 4 patients carried a much
364 lower proportion of *B. wadsworthia* (below 27.8%) compared to the average level in the healthy
365 control group (67.7%). Subsequent analysis of the 2 exceptional CD patients (Sample #47 and #128)
366 with high levels of *B. wadsworthia* revealed that the severity of disease in patient 128 was very low (2
367 mg/ml CRP), while in patient #47, no other sulphate or sulphite reducing bacterium was detected apart
368 from *B. wadsworthia*. This result is consistent with the results from the pooled data: a low proportion
369 of *B. wadsworthia* is likely to correlate with CD. However, based on the observation of these four
370 patients, effective treatment determined either by the Harvey and Bradshaw Index or by the
371 concentration of C-Reactive Protein (Table 5) does not always lead to an increase in the proportion of
372 *B. wadsworthia*. Clearly many more data from individuals before and after treatment will be required
373 for any statistically significant conclusions to be drawn. Based only on the 13 tested individuals, there
374 was no obvious association between the presence of species A and an abnormal gut environment. No or
375 very low levels of species C were found in CD patients, but it was present only in one of the 3 healthy
376 individuals investigated. Based only on the 13 tested individual samples, there was no obvious
377 association between the presence of species A or C and a healthy gut environment. The relatively high
378 proportion (approximately 6%) of species D observed in the CD patient pool was likely contributed by
379 one individual (patient sample #140), carrying species D at a level of 60% of all SRB. Again, no
380 statistically meaningful conclusion could be drawn from such a small sample.

381 Discussion

382 To our knowledge, this is the first attempt to define the relative abundance and diversity of SRB in the
383 human gut. Our primary objective was to determine by in depth sequencing of individual DNA

384 molecules whether the presence of one or more species, or their relative abundance, could be correlated
385 with gut disease. Once they had been screened for variation due to sequencing errors, highly
386 significant data were obtained. The results are therefore important in that they demonstrate that for
387 bacteria for which the more traditional method of analysing 16S-ribosomal DNA sequences is
388 unreliable, a combination of bar-coded primers and DNA sequencing of genes for a highly conserved
389 metabolic enzyme can provide a useful alternative approach to analyse complex bacterial communities
390 that might be associated with human disease.

391 Three major caveats should be considered in interpreting the data obtained from this study.
392 First, two rounds of PCR were required to generate the template molecules that were sequenced. In
393 any PCR reaction involving degenerate primers and community DNA, some templates will be
394 amplified more than others. Secondly, primer design is critical because only those templates
395 recognised by the primers can be amplified. For these reasons, it was essential to provide independent
396 data to confirm that at least the major groups of SRB present in human faeces can be detected using the
397 methods described in this study. The third caveat is that samples that failed to generate sufficient PCR
398 product could not be included in the sequencing. Thus it is conceivable, but we believe unlikely, that
399 new SRB species might occur only in these samples, and hence would have been overlooked in this
400 study. With these caveats in mind, several important conclusions can be drawn from our data.

401 Due to the scarcity of SRB in human faeces, the 1.9 kb *dsrAB* fragments produced from the first
402 round of PCR was hardly detected on an agarose gel whereas the second round PCR product, *dsrB*, was
403 visible for most samples. Thus, the amount of SRB in each patient was scored by the amount of first
404 round PCR product required to produce a clearly visible *dsrB* band on an agarose gel. The faecal
405 samples were classified into 5 groups according to the PCR scores. To explore the possibility that our
406 data were invalidated during the first round of PCR, the abundance of SRB in each individual faecal

sample was first assessed for its ability to generate a black precipitate of iron sulphide, which is indicative of SRB growth. The data correlated significantly with the PCR scores (Supplementary Fig. S22), which suggests that most of the major groups of SRB had been detected. However, there were two types of deviation from the general trend. First, 6 out of 8 of the samples from CD patients before treatment were shown to contain an inhibitor of SRB growth. The PCR assay was therefore more reliable than the growth assay for these samples. Conversely, two out of 28 UC samples (#14 and #32), two out of the 41 CD samples (#123 and 124) and 6 out of 42 IBS samples (#17, #64, #86, #90, #72 and #68) gave abundant formation of iron sulphide, but the PCR primers failed to detect the *dsrAB* genes in these samples. In this context it was surprising that no *D. fairfieldensis* was detected in any of our sample (see, for example, Loubinoux *et al.*, 2002). This bacterium has recently been implicated in human disease (Gaillard *et al.*, 2011). Thus despite the generally good correlation between growth tests and the PCR assay, further improvements to the primer set are required for the PCR assay to be completely reliable. An example of such an improvement was published after this work had been completed (Steger *et al.*, 2011).

The DGGE experiments provided an indication of the likely reliability of the second round of PCR using two independent sets of primers, but identical DNA templates. Comparable data for the relative abundance of *B. wordsworthii* and *D. piger* were obtained from both DNA sequencing and analysis of DGGE gels. This correlation extended to the three other previously characterized SRB found in individual samples. However, the DGGE method was insufficiently sensitive to be used to detect minority SRB populations

If all sulphate and sulphite reducing bacteria in each faecal DNA sample were defined as 100%, then *B. wadsworthia* and *D. piger* contributed 86% on average to the overall SRB (Table 3 and Fig 2) and were the major species of sulphate or sulphite reducing bacteria detected in this study. The

430 proportion of the two species was as high as 93.5% in the healthy control group, and lower in all
431 patient groups. After treatment, the proportion of the two species had increased slightly in all three
432 disease groups. In the CD patient group before treatment, the proportion of *B. wadsworthia* (41.9%)
433 was much lower than that in the healthy group (67.7%) or any other patient group; after treatment, the
434 proportion of *B. wadsworthia* had increased to a level similar to the healthy group. Also in this group
435 before treatment, the proportion of *D. piger* (36.7%) was higher than that in the healthy group (25.8%)
436 or any other patient group; the corresponding figure decreased to a level similar to the healthy group in
437 response to treatment. In all of the 3 patient groups, after treatment, there was always an increase, to
438 different extents, in the ratio of *B. wadsworthia* to *D. piger*. It is notable that the level of new species A
439 is very low in healthy controls (0.48%) compared to patients with any of the 3 diseases (in a range of 6
440 to 12%). Following treatment, the proportion of species A decreased in every disease group, especially
441 in CD patients (from 8.7% to 1.6%). New species C was found almost only in the healthy group; and
442 new species D was found almost only in the CD group. If these preliminary results can be confirmed in
443 a much more extensive study, they raise many interesting questions. For example, could a relatively
444 low level of *B. wadsworthia* or high level of *D. piger* be used as an indicator to distinguish CD from
445 the other 2 gut diseases? Does an effective treatment always lead to a decrease in the proportion of *D.*
446 *piger* or an increase in the proportion of *B. wadsworthia*? Could the presence of new species A be used
447 as an indicator for abnormal gut environment, or the presence of new species C be used as an indicator
448 for healthy gut environment? Does the presence of new species D contribute to the aetiology of CD?
449 Are species A B, C and D sulphate reducing bacteria, or prokaryotes that reduce organosulphur
450 compounds, or sulphite? Does the observation in pooled data reflect the distribution of SRB in each
451 individual? Finally, could the presence of a growth inhibitor in CD patients be developed as a useful
452 tool in diagnosis?

453 In summary, despite its acknowledged limitations, this study has indicated some clear
454 objectives for future research, and methods applicable to answer the many questions raised.

455 **Acknowledgement**

456 This work was funded by The Wellcome Trust (Grant No. WT080238MA).

457 **References**

- 458 Aminov RI, Walker AW, Duncan SH, Harmsen HJM, Welling GW & Flint HJ (2006) Molecular
459 diversity, cultivation, and improved detection by in situ hybridization of a dominant group of
460 human gut bacteria related to *Roseburia* spp. or *Eubacterium rectale*. *Appl Environ Microbiol* **72**:
461 6371-6376.
- 462 Chapman MAS, Grahn MF, Boyle MA, Hutton M, Rogers J & Williams NS (1994) Butyrate oxidation
463 is impaired in colonic mucosa of sufferers of quiescent ulcerative colitis. *Gut* **35**: 73-76.
- 464 Collado MC, Calabuig M & Sanz Y (2007) Difference between the faecal microbiota of coeliac infants
465 and healthy controls. *Curr Issues Intest Microbiol* **8**: 9-14.
- 466 Dear KLE, Elia M & Hunter JO (2005) Do interventions which reduce colonic fermentation improve
467 symptoms of irritable bowel syndrome? *Dig Dis Sci* **50**: 758-766.
- 468 Duffy M, O'Mahony L, Coffey JC, Collins JK, Shanahan F, Redmond HP & Kirwan WO (2002)
469 Sulfate-reducing bacteria colonize pouches formed for ulcerative colitis but not for familial
470 adenomatous polyposis. *Dis Colon Rectum* **45**: 384-388.
- 471 Gaillard T, Pons S, Darles C, Beausset O, Monchal T & Brisou P (2011) *Desulfovibrio fairfieldensis*
472 bacteremia associated with acute sigmoiditis. *Med Mal Infect* **41**: 267-268.

473 Geets J, Borrenans B, Diels L, Springael D, Vangronsveld J, van der Lelie D & Vanbroekhoven K
 474 (2006) DsrB gene-based DGGE for community and diversity surveys of sulphate-reducing bacteria.
 475 *J Microbiol Methods* **66**: 194-205.

476 Hamer HM, Jonkers D Venema K, Vanhoutvin S, Troost FJ & Brummer RJ (2008) Review article: the
 477 role of butyrate in colonic function. *Aliment Pharmacol Ther* **27**: 104-119.

478 Harvey RF & Bradshaw JM (1980) A simple index of Crohn's disease activity *Lancet* **1**: 54.

479 Jia W, Whitehead RN, Griffiths L, Dawson C, Waring RH, Ramsden DB, Hunter JO & Cole JA (2010)
 480 Is the abundance of *Faecalibacterium prausnitzii* relevant to Crohn's disease? *FEMS Microbiol*
 481 *Lett* **310**: 138-144.

482 King TS, Woolner JT & Hunter JO (1997) Dietary treatment of Crohn's disease. *Aliment Pharm*
 483 *Toxicol* **11**: 17-31.

484 King TS, Elia M & Hunter JO (1998) Abnormal colonic fermentation in irritable bowel syndrome.
 485 *Lancet* **352**: 1187-1189.

486 Kjeldsen KU, Loy A, Jakobsen TF, Thomsen TR, Wagner M & Ingvorsen K (2007) Diversity of
 487 sulphate-reducing bacteria from an extreme hypersaline sediment. Great Salt Lake (Utah). *FEMS*
 488 *Microbiol Ecol* **60**: 287-298.

489 Loubinoux J, Bronowski J-P, Pereira IAC, Mougénel J-L & Faou AEL (2002) Sulphate-reducing
 490 bacteria in human feces and their association with inflammatory bowel disease. *FEMS Microbiol*
 491 *Ecol* **40**: 107-112.

492 Louis P & Flint HJ (2009) Diversity, metabolism and microbial ecology of butyrate-producing bacteria
 493 from the human large intestine. *FEMS Microbiol Lett* **294**: 1-8.

494 Louis P, Young P, Holtrop G & Flint HJ (2009) Diversity of human colonic butyrate-producing
 495 bacteria revealed by analysis of the butyryl-CoA:acetate CoA-transferase gene. *Environ Microbiol*
 496 In press.

497 Macpherson A, Khoo UY, Forgacs I, Philpott-Howard J & Bjarnason I (1996) Mucosal antibodies in
 498 inflammatory bowel disease are directed against intestinal bacteria. *Gut* **38**: 365-375.

499 Mai V & Draganov PV (2009) Recent advances and remaining gaps in our knowledge of associations
 500 between gut microbiota and human health. *World J Gastroenterol* **15**: 81-85.

501 Manichanh C, Rigottier-Gois L, Bonnaud E, Gloux K, Pelletier E, Frangeul L, Nalin R, Jarrin C,
 502 Chardon P, Marteau P, Roca J & Dore J (2006) Reduced diversity of faecal microbiota in Crohn's
 503 disease revealed by a metagenomic approach. *Gut* **55**: 205-211.

504 Marquet P, Duncan S, Chassard C, Bernalier-Donadille A & Flint HJ (2009) Lactate has the potential
 505 to promote hydrogen sulphide formation in the human colon. *FEMS Microbiol Lett* **299**: 128-134.

506 Miletto M, Bodelier PL & Laanbroek HJ (2007) Improved PCR-DGGE for high resolution diversity
 507 screening of complex sulfate-reducing prokaryotic communities in soils and sediments. *J Microbiol*
 508 *Methods* **70**: 103-111.

509 Mills DJS, Tuohy KM, Booth J, Buck M., Crabbe MJC, Gibson GR & Ames JM (2008) Dietary
 510 glycosylated protein modulates the colonic microbiota towards a more detrimental composition in
 511 ulcerative colitis patients and non-ulcerative colitis subjects. *J Appl Microbiol* **105**: 706-714.

512 Ohge H, Furne JK, Springfield J, Rothenberger DA, Madoff RD & Levitt MD (2005) Association
 513 between fecal hydrogen sulphide production and pouchitis. *Dis Colon Rectum* **48**: 469-475.

514 Pitcher MCL & Cummings JH (1996) Hydrogen sulphide: a bacterial toxin in ulcerative colitis? *Gut*
 515 **39**: 1-4.

516 Pitcher MCL, Beatty ER & Cummings JH (2000) The contribution of sulphate reducing bacteria and 5-
 517 aminosalicyclic acid to faecal sulphide in patients with ulcerative colitis. *Gut* **46**: 64-72.

518 Postgate JR (1984) Genus *Desulfovibrio* Desulfovibrio Kluyver and van Niel 1936. In NL Krieg & JG
 519 Holt (ed.) Bergey's manual of systematic bacteriology, vol.1, p. 666-672. The Williamms and
 520 Wilkins Co., Baltimore, MD.

521 Roediger WEW, Moore J & Babidge W (1997) Colonic sulphide in pathogenesis and treatment of
 522 ulcerative colitis. *Dig Dis Sci* **42**: 1571-1579.

523 Schofield WN (1985) Predicting basal metabolic rate, new standards and review of previous work.
 524 *Hum Nutr Clin Nutr* **39C**: 5-41.

525 Shatalin K, Shatalina A, Mironov A & Nudler E (2011) H₂S: A universal defense against antibiotics in
 526 bacteria. *Science* **335**: 986-990.

527 Sokol H, Pigneur B, Watterlot L, Lakhdari O, Bermudez-Humaran LG, Gratadoux JJ *et al.* (2008)
 528 *Faecalibacterium prausnitzii* is an anti-inflammatory commensal bacterium identified by gut
 529 microbiota analysis of Crohn's disease patients. *Proc Natl Acad Sci USA* **105**: 16731-16736.

530 Tazoe H, Otomo Y, Kaji I, Tanaka R, Karaki SI & Kuwahara A (2008) Roles of short chain fatty acid
 531 receptors, GPR41 and GPR43 on colonic functions. *J Physiol Pharmacol* **59 (Suppl. 2)**: 251-262.

532 van der Waaij LA, Kroese FG, Visser A, Nelis GF, Westerveld BD, Jansen PLM & Hunter JO (2004)
 533 Immunoglobulin coating of faecal bacteria in inflammatory bowel disease. *Eur J Gastroenterol*
 534 *Hepatol* **16**: 669-674.

535 Wiesner M, Naylor SJ, Copping A, Furlong A, Lynch AG, Parkes M & Hunter JO (2009) Symptom
536 classification in irritable bowel syndrome as a guide to treatment. *Scand J Gastro* **44**: 796-803.

537 Zinkevich V & Beech IB (2000) Screening of sulphate-reducing bacteria in colonoscopy samples from
538 healthy and colitic human gut mucosa. *FEMS Microbiol Ecol* **34**: 147-155.

539 Zverlov V, Klein M, Lucker S, Friedrich MW, Kellermann J, Stahl DA, Loy A & Wagner M (2005)
540 Lateral gene transfer of dissimilatory (bi)sulfite reductase revisited. *J Bacteriol* **187**: 2203-2208.

541

542 **Figure legends.**

543 **Fig. 1.** Inhibition of SRB growth by faecal suspensions prepared from samples donated by some CD
544 patients. In a sealed serum bottle, 9.5 ml of Postgate medium B was inoculated with 0.5 ml of faecal
545 suspension. Photographs were taken after 21 days of growth at 30°C. (a) Cultures inoculated with
546 sample #38, #116 and #139 were used as positive controls. The culture inoculated with sample #148
547 did not form a black precipitate of FeS possibly due to the presence of inhibitors of SRB growth. When
548 the positive controls were mixed with sample #148, growth and FeS formation were severely inhibited.
549 (b) A 0.5 ml inoculum from the cultures with sample #148 alone, or #148 plus #38, #116 or #139 were
550 subcultured into 9.5 ml of fresh Postgate B medium. After a further 21 days, cultures were
551 photographed and compared with the starting cultures. (c) Samples obtained from the same patient
552 before treatment (#82) and after treatment (#88) were mixed with a positive control #126, and the
553 effect on growth was tested. Growth SRB in the positive control samples was inhibited by 6 out of the
554 8 faecal samples from CD patients before treatment that gave a poor correlation between the level of
555 growth and abundance of *dsrB* DNA estimated by PCR.

556 **Fig. 2.** Distribution of 4 types of SRB in 7 patient groups. The histogram shows relative abundance in
557 the seven sample groups of *dsrB* DNA from four species (the sulphite reducing bacterium, *Bilophila*
558 *wadsworthia*, *Desulfovibrio piger* and two unknown species) expressed a percentage of the total
559 number of SRB sequences obtained.

560 **Fig. 3.** Consensus sequences of the 9 phylotypes found in this study and the 8 reference species. The
561 phylotype labels 100% *B. wadsworthia*, 99% *D. piger*, 98% *D. desulfuricans* F28-1 and 98%
562 *Desulfovibrio* NY682 overlap the labels of their reference species, as they are too similar to be
563 distinguished on the dendrogram.

564

565

Table 1. Abundance of SRB in human faeces estimated by recovering growth and PCR

Patient	Sample No. Before	FeS formed	PCR score	Sample No. After	FeS formed	PCR score	Patient	Sample No. Before	FeS formed	PCR score	Sample No. After	FeS formed	PCR score
Healthy							UC						
AA	11	73	5				DA	13	17	2	22	15	3
AB	15	66	5				DB	14	4	4	24	63	4
AC	16	71	5				DC	23	29	3	35	73	3
AD	37	71	5				DD	28	22	2	32	9	4
AE	40	56	5				DE	30	37	4	60	73	5
AF	42	73	4				DF	31	54	5	34	72	5
AG	43	66	5				DG	38	71	5	49	72	5
AH	44	72	5				DH	51	34	4	62	19	2
AI	50	71	4				DI	81	n/a	4	170	n/a	3
AJ	54	n/a	4				DJ	98	58	5	108	62	4
AK	71	68	5				DK	102	72	4	111	58	4
AL	74	71	4				DL	116	72	5	120	72	5
AM	95	64	4				DM	139	72	5	155	69	4
AN	114	65	4				DN	160	60	5	165	71	4
AO	145	70	5										
AP	146	58	5										
AQ	168	71	5										
AR	169	69	5										
Mean		68	4.7						46	4.1		56	3.9
STDV		5.0	0.5						24	1.1		24	0.9
IBS							CD						
BA	8	73	1	9	72	4	CA	18	56	4	27	8	2
BB	12	60	4	29	38	4	CB	39	42	5	66	24	3
BC	17	18	5	25	62	5	CC	46	32	3	56	13	3
BD	20	72	4	45	73	5	CD	47	71	4	73	43	4
BE	36	71	4	90	21	4	CE	53	69	4	61	71	5
BF	48	71	5	69	72	5	CF	57	61	5	65	65	5
BG	52	70	4	72	16	4	CG	82	9	4	88	18	4
BH	55	36	4	159	70	4	CH	93	5	5	127	73	5
BI	58	18	4	76	59	4	CI	117	58	2	123	56	1
BJ	63	42	4	70	50	1	CJ	121	29	3	141	48	4
BK	64	16	5	68	21	5	CK	124	58	1	138	47	3
BL	84	69	5	89	66	5	CL	126	66	5	163	71	5
BM	86	29	5	106	55	5	CM	128	71	5	133	72	5
BN	100	64	5	134	70	5	CN	131	7	3	136	25	1
BO	104	72	4	129	72	5	CO	137	35	1	157	59	4
BP	105	65	5	150	59	1	CP	140	72	4	147	70	5
BQ	110	70	4	115	68	4	CQ	142	70	5	149	70	5
BR	112	71	4	176	69	4	CR	143	68	4	154	72	5
BS	113	66	4	118	68	4	CS	164	71	5	172	69	5
BT	122	35	4	125	70	4	CT	166	13	3	175	19	4
BU	162	72	5	167	71	4	CU ¹	148	4	5			
Mean		55	4.2		58	4.1			48	3.8		50	3.9
STDV		21	0.9		18.5	1.1			25	1.3		23	1.3

566

567

568

569

570

Note 1. Patient CU did not donate a follow-up sample, thus his/her sample was not used for the calculation of mean and standard deviation.
n/a: not assayed.

571 **Table 2.** Pooled and individual samples used in two 454 sequencing experiments

Barcode Pool No.	Patient No.	Sample No. Before	FeS formed ¹	PCR score	Barcode Pool No.	Patient No.	Sample No. After	FeS formed ¹	PCR score
Pooled samples used for the first 454 sequencing experiment									
Healthy									
1	AA	11	73	5					
	AC	16	71	5					
	AD	37	71	5					
	AH	44	72	5					
8	AE	40	56	5					
	AG	43	66	5					
	AM	95	64	4					
	AN	114	65	4					
	AP	146	58	5					
IBS Before treatment					IBS After treatment				
4	BF	48	71	5	5	BD	45	73	5
	BL	84	69	5		BF	69	72	5
	BP	105	65	5		BN	134	70	5
	BU	162	72	5		BO	129	72	5
11	BC	17	18	5	12	BB	29	38	4
	BI	58	18	4		BE	90	28	4
	BK	64	16	5		BG	72	16	4
	BM	86	29	5		BK	68	21	5
	BT	122	35	4		BM	106	55	5
CD Before treatment					CD After treatment				
6	CL	126	66	5	7	CL	163	71	5
	CM	128	71	5		CM	133	72	5
	CQ	142	70	5		CP	147	70	5
	CP	140	72	4		CQ	149	70	5
13	CA	18	56	4	14	CD	73	43	4
	CB	39	42	5		CG	88	18	4
	CF	57	61	5		CJ	141	48	4
	CG	82	9	4		CO	157	59	4
	CH	93	5	5		CT	175	19	4
UC Before treatment					UC After treatment				
2	DG	38	71	5	3	DE	60	73	5
	DL	116	72	5		DF	34	72	5
	DM	139	72	5		DG	49	72	5
	DN	160	60	5		DL	120	72	5
9	DB	14	4	4	10	DB	24	63	4
	DE	30	37	4		DD	32	9	4
	DF	31	54	5		DJ	108	62	4
	DH	51	34	4		DK	111	58	4
	DJ	98	58	5		DM	155	69	4

572

573

Samples sequenced individually in the second 454 experiment

CD Before treatment					CD After treatment				
3	CQ	142	70	5	4	CQ	149	70	5
5	CD	47	71	4	6	CD	73	43	4
7	CG	82	9	4	8	CG	88	18	4
9	CH	93	5	5	10	CH	127	73	5
11	CM	128	71	5					
12	CP	140	72	4					
Healthy									
13	AD	37	71	5					
15	AE	40	56	5					
16	AM	95	64	4					

574 ¹: Equal quantities of DNA from 4 or 5 samples from each subgroup were sequenced. The first of the two pools
575 was from samples that generated most FeS; the second from samples that generated slightly less FeS.

Table 3. Variation of SRB in 14 patient pools including 2 subgroups for each of the 7 patient groups

	Healthy		UC Before		UC After		IBS Before		IBS After		CD Before		CD After	
Intensity of FeS in culture	High	High	High	Low	High	Low	High	Low	High	Low	High	Low	High	Low
Barcode Pool No.	1	8	2	9	3	10	4	11	5	12	6	13	7	14
No. of sequence analysed	5,729	3,141	2,204	5,326	5,672	6,003	4,001	5,639	1,593	6,078	2,061	2,290	2,990	2,981
<i>B. wadsworthia</i> (100% identical)	67.7	67.7	70.4	64.6	72.7	68.65	29.3	94.2	39.8	99.4	45.5	39.1	24.5	96.98
<i>D. piger</i> (> 99% identical)	27.25	24.5	24.2	7.1	22.8	4.5	44.7	0	36.1	0	32.2	40.3	52.2	0.1
New species A	0.95	0.1	1.3	17.35	0.7	11.8	24.7	1.9	16.7	0.65	1.4	14.5	0	2.92
New species B	0.6	3.9	4.1	10.55	3.8	1.4	0.2	0	1.3	0	6.5	2.6	0.4	0
New species C	2.75	3.2	0	0	0	0	0.2	0.1	0	0	0	0.1	0	0
<i>D. vulgaris</i> Hildenborough (> 97% identical)	0	0	0	0	0	14.1	0	3.4	0	0	0	0	0.7	0
<i>Desulfovibrio</i> NY682 (> 98% identical)	0.55	0	0	0	0	0	0.0	0	0	0	0	2.6	9.9	0
<i>D. desulfuricans</i> F28-1 (> 98% identical)	0	0	0	0	0	0	0.6	0	6.0	0	0.0	0.6	0	0
New species D	0	0	0	0	0	0	0.0	0	0	0	15	0	12.1	0
Other	0.2	0.6	0	0.4	0	0.04	0.3	0.4	0.1	0	0	0.2	0	0
All SRB %	100	100	100	100	100	100	100	100	100	100	100	100	100	100

Table 4. Diversity of SRB in individual patients

Patient No.	Patients with Crohn's disease										Healthy controls		
	CQ		CD		CG		CH		CM	CP	AD	AE	AM
Sample No.	Before 142	After 149	Before 47	After 73	Before 82	After 88	Before 93	After 127	Before 128	Before 140	37	40	95
Intensity of black FeS in culture	High	High	High	Low	Low	Low	Low	High	High	High	High	High	High
No. of sequences analysed	2,999	2,985	1,238	2,976	3,001	2,987	2,993	2,975	3,000	2,999	3,000	2,998	3,010
<i>B. wadsworthia</i> (100% identical)	27.81	6.47	100	99.66	3.97	100	5.15	10.18	88.3	0	90.77	100	37.77
<i>D. piger</i> (> 99% identical)	70.92	92.13	0	0.34	0	0	94.29	88.84	0	37.91	0	0	62.19
New species A	0	0	0	0	91.2	0	0.13	0	0.9	1.63	3.2	0	0
New species B	0	0	0	0	0	0	0	0	10.8	0	0	0	0
New species C	0	0	0	0	0	0	0.17	0	0	0	5.73	0	0
<i>D. vulgaris</i> Hildenborough (> 97% identical)	0	0	0	0	0	0	0	0	0	0	0	0	0
<i>Desulfovibrio</i> NY682 (> 98% identical)	0	0	0	0	0	0	0	0	0	0	0	0	0
<i>D. desulfuricans</i> F28-1 (> 98% identical)	0	0	0	0	4.83	0	0	0	0	0	0	0	0
New species D	1.27	1.41	0	0	0	0	0.27	0.34	0	60.42	0	0	0.33
Other	0	0	0	0	0	0	0	0.64	0	0.03	0.3	0	0
All SRB %	100	100	100	100	100	100	100	100	100	100	100	100	100

Table 5. Clinical response of patients with Crohn's disease to treatment as measured by the analysis of C-reactive protein (CRP) and the Harvey & Bradshaw Index.

Patient No.	Sample No. Before	Harvey & Bradshaw Index	CRP (mg/l)	Sample No. After	Harvey & Bradshaw Index	CRP (mg/l)
CA	18	9	96	27	7	7
CB	39	5	6	66	0	1
CC	46	7	5	56	3	2
CD	47	7	76	73	0	10
CE	53	6	n/a	61	3	n/a
CF	57	8	n/a	65	2	n/a
CG	82	15	33	88	2	1
CH	93	12	5	127	1	3
CI	117	6	5	123	2	2
CJ	121	4	10	141	0	12
CK	124	8	n/a	138	2	n/a
CL	126	5	n/a	163	5	40
CM	128	4	2	133	0	6
CN	131	8	97	136	2	14
CO	137	3	4	157	3	3
CP	140	11	2	147	3	n/a
CQ	142	8	27	149	2	5
CR	143	4	6	154	1	4
CS	164	9	56	172	2	n/a
CT	166	12	n/a	175	8	n/a



DSPACE

<https://dspace.org/>

Diversity and distribution of sulphate-reducing bacteria in human faeces from healthy subjects and patients with inflammatory bowel disease

Jia, Wenjing; Whitehead, Rebekah N.; Griffiths, Lesley; Dawson, Claire; Bai, Hao ...

2012-06-01T00:00:00Z

<http://dx.doi.org/10.1111/j.1574-695X.2012.00935.x>

Wenjing Jia, Rebekah N. Whitehead, Lesley Griffiths, Claire Dawson, Hao Bai, Rosemary H. Waring, David B. Ramsden, John O. Hunter, Michael Cauchi, Conrad Bessant, Dawn P. Fowler, Christopher Walton, Claire Turner and Jeffrey A. Cole. Diversity and distribution of sulphate-reducing bacteria in human faeces from healthy subjects and patients with inflammatory bowel disease. FEMS Immunology and Medical Microbiology, Volume 65, Issue 1, pages 55–68, June 2012.